ABBV - AbbVie Inc.

AbbVie is a pharmaceutical company whose flagship product is Humira (adalimumab), a biologic TNF inhibitor used to treat rheumatoid arthritis, psoriasis, and Crohn's disease, though its newer immunology drugs Skyrizi and Rinvoq are now the primary growth drivers as Humira faces biosimilar competition. The business model is prescription pharmaceutical: drugs are developed and sold to hospitals, specialty pharmacies, and healthcare providers, with reimbursement driven by insurance payers and government programs like Medicare and Medicaid. AbbVie generates approximately $56B in annual revenue, with the United States accounting for roughly 60% of sales; the company also has a significant oncology and neuroscience portfolio following its 2020 acquisition of Allergan, which added Botox to its product lineup.

Past Year Trends

• Skyrizi (risankizumab) net revenues grew approximately 51% year-over-year to roughly $10.4 billion in FY2024, fueled by FDA approvals for Crohn's disease and ulcerative colitis that extended its reach well beyond the original plaque psoriasis indication. (Bullish)
• AbbVie closed the $10.1 billion acquisition of ImmunoGen in February 2024, adding mirvetuximab soravtansine (ELAHERE) for platinum-resistant ovarian cancer and marking the company's largest oncology commitment in over a decade. (Neutral)
• Emraclidine, the lead schizophrenia asset from AbbVie's $8.7 billion Cerevel Therapeutics acquisition, reported Phase 2 EMPOWER trial failure in mid-2025, eliminating the primary strategic rationale for the deal and sending ABBV shares down roughly 13% on the announcement date. (Bearish)

Next Year Trends

• Tavapadon, a selective D1/D5 partial agonist for Parkinson's disease and the primary remaining pipeline asset from the Cerevel acquisition, has Phase 3 readouts expected in the 2025-2026 window that will determine whether AbbVie can recover any material value from its $8.7 billion neuroscience investment. (Bullish)
• Skyrizi and Rinvoq are targeting a combined peak net revenue of over $27 billion, with gastroenterology market-share execution against competitors including Eli Lilly's mirikizumab in Crohn's disease and UC being the single largest variable in whether AbbVie hits its own long-term guidance over the next 12 months. (Bullish)
• U.S. Humira revenues, which declined to approximately $8.9 billion in FY2024 from a pre-biosimilar peak near $17 billion, are expected to fall further toward a structural floor in 2025-2026 as biosimilar penetration matures, though the incremental annual drag is now meaningfully smaller than during the 2023-2024 erosion phase. (Neutral)

Red Flags

No severe red flags identified as of August 2025.